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CD4-based decoy approaches against HIV-1 are attractive options
for long-term viral control, but initial designs, including soluble
CD4 (sCD4) and CD4-Ig, were ineffective. To evaluate a therapeutic
that more accurately mimics HIV-1 target cells compared with mo-
nomeric sCD4 and dimeric CD4-Ig, we generated virus-like nano-
particles that present clusters of membrane-associated CD4 (CD4-
VLPs) to permit high-avidity binding of trimeric HIV-1 envelope
spikes. In neutralization assays, CD4-VLPs were >12,000-fold more
potent than sCD4 and CD4-Ig and >100-fold more potent than the
broadly neutralizing antibody (bNAb) 3BNC117, with >12,000-fold
improvements against strains poorly neutralized by 3BNC117.
CD4-VLPs also neutralized patient-derived viral isolates that were
resistant to 3BNC117 and other bNAbs. Intraperitoneal injections
of CD4-CCR5-VLP produced only subneutralizing plasma concen-
trations in HIV-1–infected humanized mice but elicited CD4-
binding site mutations that reduced viral fitness. All mutant
viruses showed reduced sensitivity to sCD4 and CD4-Ig but
remained sensitive to neutralization by CD4-VLPs in vitro. In vitro
evolution studies demonstrated that CD4-VLPs effectively con-
trolled HIV-1 replication at neutralizing concentrations, and viral
escape was not observed. Moreover, CD4-VLPs potently neutral-
ized viral swarms that were completely resistant to CD4-Ig, sug-
gesting that escape pathways that confer resistance against
conventional CD4-based inhibitors are ineffective against CD4-
VLPs. These findings suggest that therapeutics that mimic HIV-1
target cells could prevent viral escape by exposing a universal vul-
nerability of HIV-1: the requirement to bind CD4 on a target cell.
We propose that therapeutic and delivery strategies that ensure
durable bioavailability need to be developed to translate this con-
cept into a clinically feasible functional cure therapy.
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Antiretroviral therapy (ART) prolongs the life expectancy ofHIV-1–infected individuals but is associated with side ef-
fects, and multiple drugs need to be given in combination to
prevent the development of viral resistance (1). In addition,
treatment must continue for the lifetime of the individual due to
the existence of a long-lived latent proviral reservoir. While a
“sterilizing” cure remains difficult to achieve due to difficulties
associated with identifying and clearing latently infected cells (2,
3), recent research has focused on designing a “functional” cure,
i.e., a therapeutic strategy that enables long-term suppression of
HIV-1 replication and remission of symptoms in the absence of
ART (4).
The development of viral resistance is a major obstacle to
achieving a functional cure, since low levels of latent replication-
competent viruses persist in the body. Decoy approaches that
closely mimic HIV-1 target cells are attractive options for long-
term viral control, as viral resistance through mutation cannot
develop without concomitant loss of target cell infectivity (5, 6).
HIV-1 primarily infects CD4+ T cells; the gp120 subunit of the
viral envelope glycoprotein (Env) initially binds CD4, triggering
a conformational change that allows it to interact with a host cell
coreceptor protein, the chemokine receptor CCR5 or CXCR4,
leading to fusion between the viral and host cell membranes (7).
Initial attempts to design decoys against HIV-1 used a soluble
form of CD4 (sCD4) to block the receptor-binding sites on Env,
but this strategy proved ineffective in patients (8, 9). Subsequent
studies revealed that many primary HIV-1 isolates were rela-
tively insensitive to sCD4 neutralization without apparent loss of
viral fitness (10). In addition, HIV-1 can develop resistance to
CD4-based inhibitors by acquiring mutations in the CD4-binding
site (CD4bs) on gp120 that lower its affinity for CD4 (11–13)
(Fig. 1). A potential explanation for the shortcomings of sCD4
therapy is that monomeric sCD4 fails to accurately mimic an
HIV-1 target cell in which clusters of CD4 molecules on the
membrane could enable Env, a trimeric protein with three
CD4bs, to form multiple interactions that tether it to the cell
surface (14). Thus, HIV-1 variants could escape from sCD4-
mediated inhibition through avidity effects that compensate for
a lower intrinsic sCD4-binding affinity by using multivalent in-
teractions, thereby retaining the ability to efficiently infect target
cells. Dimeric CD4-Ig fusion proteins (CD4-Ig) (15) do not
overcome this problem, since bivalent binding with both CD4
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arms is prevented by the low density of Env spikes on the viral
surface and/or the architecture of single Env trimers (16–18)
(Fig. 1).
To test this hypothesis, we generated HIV-1 Gag-based virus-
like nanoparticles that present clusters of CD4 in its natural
membrane-associated conformation (CD4-VLPs) (Fig. 1). We
demonstrate that CD4-VLPs neutralize HIV-1 with enhanced
potency and breadth compared with sCD4, CD4-Ig, and
3BNC117, a broadly neutralizing antibody (bNAb) that targets
the CD4bs. We also show that viral escape pathways that confer
resistance to sCD4 and CD4-Ig are ineffective against CD4-
VLPs, suggesting that therapeutics that mimic HIV-1 target
cells could prevent viral escape by exposing a universal vulner-
ability, the requirement to bind clusters of CD4 on a target cell.
Results
CD4-VLPs Potently Neutralize HIV-1. CD4-VLPs were generated by
transiently coexpressing HIV-1 Gag and CD4 in Expi293 cells.
When expressed in human cells, the Gag polyprotein self-assembles
into immature core particles that form ∼120-nm-diameter VLPs by
budding through the plasma membrane (19). CD4-CCR5-VLPs
were also generated to investigate whether adding a coreceptor
would enhance the potency and breadth of HIV-1 neutralization.
VLPs were collected from transfected cell supernatants and con-
centrated by centrifugal filtration or sucrose cushion ultracentrifu-
gation (Methods). Western blot analysis confirmed that CD4 and
CCR5 were present on CD4-VLPs and CD4-CCR5-VLPs, respec-
tively, but not on control VLPs (Fig. 2A). To determine VLP
concentrations, we converted p24 measurements from ELISAs
against the Gag p24 capsid protein into VLP concentrations by
assuming that each VLP contains 2,000 copies of Gag (20, 21)
(Methods). Typical VLP concentrations in transfected supernatants
were ∼1010 VLPs/mL, which could be concentrated to ∼1011 VLPs/
mL. To estimate the number of CD4 molecules per VLP, we
combined supernatants from five independent CD4-VLP produc-
tions and purified CD4-VLPs using sucrose cushion ultracentrifu-
gation and size exclusion chromatography (SI Appendix, Fig. S1 A
and B). Quantitative Western blot analysis showed that purified
CD4-VLPs contained the Gag-EGFP fusion protein and CD4 at a
molar ratio of ∼14:1 (SI Appendix, Fig. S2 A–C), suggesting that
CD4-VLPs incorporated an average of 140 ± 48 molecules of CD4.
Cryo-electron tomography (cryo-ET) imaging of purified CD4-
VLPs revealed spherical particles of ∼120 nm diameter with dis-
cernible internal layers of immature Gag (Fig. 2B and Movie S1).
Although membrane-bound CD4 molecules are too small to be
visualized by cryo-ET, their presence on a number of CD4-VLPs,
but not on control VLPs, was confirmed by densities for bound
soluble Env trimers (Fig. 2B and Movie S1). However, since there is
no specific mechanism for packaging CD4 and CCR5 into HIV-1
Gag-based VLPs, CD4-VLPs containing little or no CD4 were
also observed.
The ability of CD4-VLPs to inhibit HIV-1 infection of target
cells was evaluated using pseudovirus-based TZM-bl neutrali-
zation assays (22). CD4-VLPs and CD4-CCR5-VLPs neutralized
the HIV-1 strain YU2 at half maximal inhibitory concentrations
(IC50s) of 0.012 μg p24/mL and 0.006 μg p24/mL, equivalent to
1.5 × 108 and 0.8 × 108 VLPs/mL, respectively (Fig. 2C). Control
VLPs showed no neutralization at concentrations up to 1.5 ×
1010 VLPs/mL. Neutralization activity was independent of the
VLP purification method and similar for different batches of
CD4-VLPs (SI Appendix, Fig. S3). A concentration of 2.1 × 1010
CD4 molecules/mL (0.0017 μg/mL) (calculated assuming that
each CD4-VLP displays 140 copies of CD4) was required to
achieve 50% neutralization. The comparable neutralization
profiles of CD4-VLPs and CD4-CCR5-VLPs suggested that the
presence of CD4 on VLPs was sufficient for potent HIV-1
neutralization in the absence of CCR5. Extracellular vesicles
naturally secreted by eukaryotic cells (23) did not contribute to
the neutralization activity of CD4-VLPs, as supernatants from
sCD4 CD4-Ig
CD4-based inhibitor 
neutralizes HIV-1 
CD4bs mutations 
in Env prevent 
binding of sCD4 
but not CD4 on VLPs 
HIV-1 with mutated Envs 
can still infect target cells 
due to high-avidity 
interactions with CD4
CD4-VLPs
Fig. 1. CD4-VLPs can overcome HIV-1 Env mutations that prevent neutral-
ization by soluble CD4-based inhibitors. Schematic comparison of responses
of soluble CD4-based inhibitors and CD4-VLPs to Env mutations. Monovalent
sCD4 and bivalent CD4-Ig neutralize sCD4-sensitive strains (purple Env tri-
mers; row 1), but mutations in the CD4bs that lower the affinity of Env for
sCD4 (yellow Env trimers; row 2) render other strains resistant to soluble
CD4-based inhibitors while maintaining the ability to infect CD4+ target cells
via avidity effects through binding to multiple CD4 receptors tethered to the
host cell membrane (row 3). CD4-VLPs can neutralize viral strains that are
resistant to soluble CD4-based inhibitors through high-avidity binding to
multiple CD4 receptors tethered to the VLP membrane.
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Fig. 2. VLPs incorporate CD4 and CCR5 and neutralize HIV-1. (A) Western
blot analysis to detect CD4 (Left) and CCR5 (Right) in supernatants con-
taining HIV-1 Gag-derived VLPs from Expi293 cells transfected with Gag
alone (control VLPs; lane 1), Gag and CD4 (CD4-VLPs; lane 2), Gag, CD4, and
CCR5 (CD4-CCR5-VLPs; lane 3). (B) Tomographic slices (10.9 nm) from cryo-ET
analysis of control VLPs (Left) or CD4-VLPs (Right three panels) incubated
with a soluble native-like Env trimer (BG505 SOSIP.664). (Scale bar: 20 nm.)
Red arrows indicate densities for bound Env trimers. Approximate positions
of immature Gag shell layers are highlighted in the Left two panels. Note the
hexagonal lattice in the capsid layer of Gag. See also Movie S1. (C) In vitro
neutralization assay against HIV-1YU2 pseudovirus comparing control VLPs,
CD4-VLPs, and CD4-CCR5-VLPs. The neutralization activity of VLPs was de-
termined in terms of concentrations of the Gag p24 capsid protein. Data
points are presented as the mean and SD of duplicate measurements.
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cells transfected with CD4 in the absence of Gag had no effect
(SI Appendix, Fig. S4 A and B).
CD4-VLPs Neutralize HIV-1 with Enhanced Potency and Breadth
Compared with sCD4, CD4-Ig, and a CD4bs bNAb. To investigate
whether CD4 multimerization enhances the potency and breadth
of CD4-based inhibitors, the neutralization activity of CD4-VLPs
was compared with that of monovalent sCD4, bivalent CD4-Ig,
and 3BNC117 IgG, a CD4bs bNAb that has been evaluated in
human clinical trials (24, 25). Potency and breadth were com-
pared by quantifying the number of CD4 molecules (CD4-VLPs,
sCD4, CD4-Ig) or antigen-binding fragments (Fabs; 3BNC117)
required to neutralize a panel of 12 HIV-1 Env reference strains
representing the global HIV-1 epidemic (26).
CD4-VLPs neutralized all 12 strains with a geometric mean
IC50 of 1.3 × 10
8 VLPs/mL (SI Appendix, Table S1). CD4-CCR5-
VLPs did not show an overall enhanced potency compared with
CD4-VLPs (geometric mean IC50 = 1.2 × 10
8 VLPs/mL). As-
suming ∼140 copies of CD4 per VLP (SI Appendix, Fig. S2 A–C),
neutralization was achieved at a geometric mean IC50 of 1.9 ×
1010 CD4 molecules/mL (Fig. 3A and SI Appendix, Table S1).
sCD4 and CD4-Ig neutralized only nine (sCD4) or seven (CD4-
Ig) of 12 strains with geometric mean IC50 values of 10.0 and 27.7
μg/mL, respectively, equivalent to 2.3 × 1014 and 3.3 × 1014 CD4
molecules/mL (Fig. 3A and SI Appendix, Table S2). These results
demonstrate that CD4-mediated neutralization of HIV-1
is >12,000-fold more potent for multivalent CD4, likely due to
high-avidity interactions between clustered CD4 receptors and
HIV-1 Env.
CD4-VLPs were also more potent and broad than 3BNC117,
which neutralized 11 of 12 strains with a geometric mean IC50 of
0.31 μg/mL (2.5 × 1012 Fabs per mL) (Fig. 3A and SI Appendix,
Table S2). Thus, the geometric mean IC50 of CD4 molecules on
CD4-VLPs was >100-fold lower than the required concentration
of 3BNC117 Fabs and >12,000-fold lower for the X1632, CH119,
and BJOX2000 strains, which are relatively insensitive to
3BNC117. Interestingly, there was only a 15-fold difference be-
tween the highest and lowest IC50 values against the 12 strains
for CD4-VLPs, compared with a 4,500-fold difference for
3BNC117, highlighting the excellent neutralization breadth of
CD4-VLPs.
The neutralization activity of CD4-VLPs was also evaluated
against primary isolates obtained from two previously described
HIV-1–infected patients (27). These isolates were poorly neu-
tralized by bNAbs targeting various epitopes on Env, including
the CD4bs, V1V2, the membrane-proximal external region, and
the gp120–gp41 interface (IC50 >1 μg/mL) (Fig. 3B and SI Ap-
pendix, Table S3). However, both isolates were potently neu-
tralized by CD4-VLPs at concentrations similar to IC50 values
determined against the HIV-1 strains in the 12-strain panel.
Comparing the numbers of CD4 and Fab molecules required for
50% neutralization revealed that CD4-VLPs were 500- to
11,000-fold more potent than the CD4bs bNAb 3BNC117.
Similar differences in potency were also observed when com-
paring CD4-VLPs with bNAbs targeting epitopes other than the
CD4bs. These results demonstrate that primary HIV-1 isolates
that are resistant to multiple bNAbs can be potently neutralized
by a therapeutic that mimics HIV-1 target cells.
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Fig. 3. CD4-VLPs neutralize HIV-1 with enhanced potency and breadth compared with sCD4, CD4-Ig, and 3BNC117. (A) In vitro neutralization of HIV-1YU2 and
a panel of 12 HIV-1 Env reference strains (26). IC50 values against each strain and the geometric mean IC50 are presented as CD4 copies/mL for CD4-VLPs, sCD4,
and CD4-Ig and as Fab copies/mL for 3BNC117 (SI Appendix, Tables S1 and S2). IC50 values of 50 μg/mL were used for strains that were not neutralized at
50 μg/mL by sCD4, CD4-Ig, and 3BNC117 for the geometric mean IC50 calculations. (B) In vitro neutralization of two HIV-1 patient isolates that exhibited
resistance against multiple bNAbs (27). IC50 values are presented in CD4 copies/mL for CD4-VLPs and in Fab copies/mL for 3BNC117 (CD4bs bNAb), PGDM1400
(V1V2 bNAb), 10E8 (membrane-proximal external region bNAb), and 8ANC195 (gp120–gp41 interface bNAb) (SI Appendix, Table S3).
Hoffmann et al. PNAS | August 4, 2020 | vol. 117 | no. 31 | 18721
M
IC
RO
BI
O
LO
G
Y
D
ow
nl
oa
de
d 
at
 C
al
ifo
rn
ia
 In
st
itu
te
 o
f T
ec
hn
ol
og
y 
on
 A
ug
us
t 6
, 2
02
0 
CD4-CCR5-VLP Treatment in HIV-1–Infected Hu-Mice Elicits CD4bs
Mutations in HIV-1 Env Despite Poor Bioavailability. We investi-
gated the ability of CD4-CCR5-VLPs to suppress HIV-1 repli-
cation and prevent viral escape in vivo in HIV-1YU2–infected
humanized mice (hu-mice). CD4-CCR5-VLPs were selected for
in vivo experiments to prevent the potential emergence of CD4-
independent HIV-1 escape variants (28–30). To determine an
optimal administration regimen, initial half-life studies were
performed in uninfected hu-mice. Here, 7.6 × 109 CD4-CCR5-
VLPs (610 ng of p24) were intraperitoneally (IP) injected into
five hu-mice. Blood samples were taken from one animal per
time point after 20 min, 1 h, 2 h, 4 h, and 6 h, and plasma CD4-
CCR5-VLP concentrations were measured by p24 ELISA. CD4-
CCR5-VLP concentrations were either slightly above or slightly
below the detection limit of 1.5 ng p24/mL (1.9 × 107 VLPs/mL)
at all time points. A peak concentration of 8.5 × 107 VLPs/mL
was measured at 1 h postinjection. Incomplete diffusion across
the peritoneal membrane into the hepatic portal vein and rapid
hepatic clearance (31) likely contributed to the poor bioavail-
ability of CD4-CCR5-VLPs administered IP. These studies
showed that IP administrations of CD4-CCR5-VLPs reached
only subneutralizing plasma concentrations, as peak levels were
lower than in vitro neutralization IC50 values against HIV-1YU2
(SI Appendix, Table S1).
To achieve maximal plasma concentrations for experiments in
HIV-1YU2–infected mice, 6 × 10
9 control or CD4-CCR5-VLPs
were injected IP twice daily for 10 d. This regimen failed to
maintain detectable plasma VLP concentrations, as control
VLPs and CD4-CCR5-VLPs were undetectable at 6 h postin-
jection on day 6 of treatment. The efficacy of CD4-CCR5-VLP
treatment was compared with that of twice-weekly IP injections
of 1 mg of 10–1074, a V3-glycan patch bNAb currently being
evaluated in human clinical trials (32). While 10–1074 treatment
achieved robust reductions in viral loads in all treated animals,
control and CD4-CCR5-VLPs had no effect on viral loads
(Fig. 4A).
To investigate whether intermittent subneutralizing CD4-
CCR5-VLP plasma concentrations exert selective pressure on
HIV-1 in vivo, the circulating plasma viruses of two HIV-
1–infected control VLP-treated animals and three CD4-CCR5-
VLP–treated animals were analyzed by single-genome sequencing
on day 10 after treatment cessation. Four recurring mutations—
G366E, G458D/S, E466K, and G471R—were observed in the
gp120 subunits of the HIV-1YU2 Envs obtained from CD4-CCR5-
VLP–treated hu-mice but were rare or absent from sequences
derived from control VLP-treated animals (Fig. 4B). All individual
mutations occurred in at least two animals and were mutually
exclusive, except for one gp120 sequence that contained both
G458D and G471R mutations. Together, these variants accounted
for 61.5% of the env genes sequenced from CD4-CCR5-VLP–
treated hu-mice, indicating that these mutations provided a se-
lective advantage in the presence of intermittent subneutralizing
CD4-CCR5-VLP plasma concentrations. Interestingly, in one
CD4-CCR5-VLP–treated mouse, these mutations were found in
75% of the viruses (SI Appendix, Fig. S5).
The substitutions mapped to residues in close proximity to the
CD4bs in the gp120 subunit of Env (Fig. 4C), suggesting that the
mutations reduced the ability of Env to bind CD4, thereby po-
tentially allowing escape from CD4-based reagents. Indeed, the
G366E (33), G458D (34), and G471R (13) mutations have been
reported to confer partial resistance against CD4-based inhibi-
tors. No recurrent mutations were found near the coreceptor-
binding site, indicating that selective pressure was exerted pri-
marily by CD4 on the CD4-CCR5-VLPs. All mutated residues
are highly conserved among HIV-1 Env sequences, whereas the
substitutions in the variants are rare (Fig. 4D), suggesting that
these mutations could compromise viral fitness.
HIV-1YU2 Variants Are Less Infectious and Not Resistant to CD4-VLPs.
Surface plasmon resonance (SPR) studies were performed to
determine whether the recurring mutations in env sequences
from HIV-1–infected and CD4-CCR5-VLP–treated animals af-
fected the CD4-binding affinity of HIV-1YU2 gp120. Potential
avidity effects were avoided by injecting monomeric gp120 pro-
teins (YU2wt gp120 and each YU2 gp120 variant) over immo-
bilized CD4-Ig (SI Appendix, Fig. S6A). The YU2G366E gp120
mutant was excluded from the SPR analysis, as gel electropho-
resis showed that this protein was unstable and migrated as
multiple species (SI Appendix, Fig. S6B).
Changes in CD4 binding were most evident for YU2G458D
gp120, which dissociated 11-fold faster than YU2wt gp120
(Fig. 5A and SI Appendix, Table S4). Weaker binding of this
mutant was expected, as the Gly in YU2wt gp120 directly inter-
acts with CD4, whereas the substituted Asp introduced a nega-
tive charge and potential steric clashes at this position (Fig. 4C).
Changes in the CD4-binding affinity for the YU2E466K and
YU2G471R gp120 mutants were less pronounced, since residues
at both positions do not directly interact with CD4 (Fig. 4C).
However, both substitutions introduced positive charges that
could destabilize the CD4bs. Although SPR measurements were
not possible for YU2G366E gp120, the substitution introduces a
larger side chain and a negative charge into a residue that di-
rectly contacts CD4, and thus it seems likely that YU2G366E
gp120 binds CD4 more weakly than YU2wt gp120.
To ascertain whether the changes in CD4-binding affinity di-
rectly impacted the ability of HIV-1 to infect target cells, we
performed in vitro infection assays using HIV-1YU2 pseudovi-
ruses carrying the observed mutations in gp120. Equivalent
amounts of p24 (40 pg) were added to target cells for YU2wt and
the YU2 variant pseudoviruses, and luciferase expression was
monitored in CD4+/CCR5+ TZM-bl cells as a measure of HIV-1
infectivity. Infection was greater for the wild-type YU2 virus than
for the variants (Fig. 5B); three of the mutant viruses (YU2G366E,
YU2E466K, and YU2G471R) were 3.8- to 6.6-fold less infectious
than YU2wt, while a 24-fold reduction in viral entry fitness was
observed for the YU2G458D variant. The decreased infectivity of
the mutant viruses could be related to changes affecting their
binding to CD4, particularly for the YU2G458D variant.
In vitro neutralization assays were performed to determine
whether the mutations confer resistance to CD4-VLPs and CD4-
CCR5-VLPs. All mutant viruses were ∼30-fold less sensitive than
YU2wt to sCD4 and CD4-Ig (Fig. 5C and SI Appendix, Table S5).
Surprisingly, the mutant viruses were neutralized by CD4-VLPs
and CD4-CCR5-VLPs at equivalent concentrations to those re-
quired for neutralization of the wild-type virus. This suggests that
the mutations provided a selective advantage when exposed to
short-lived, subneutralizing concentrations of CD4-CCR5-VLPs
but did not decrease viral sensitivity to neutralizing CD4-VLP or
CD4-CCR5-VLP concentrations. This demonstrates that CD4bs
mutations that enable viral escape against conventional CD4-
based inhibitors would not confer resistance to CD4-VLPs.
To investigate whether HIV-1 is able to escape when exposed
to neutralizing CD4-VLP concentrations, we performed in vitro
evolution experiments. Replication-competent HIV-1YU2 was
propagated on the Rev-A3R5 CD4+ T cell reporter line (35) for
21 d to generate a diversified viral population. Infection rates
were maintained at ∼10% of infected cells by transferring the
viral supernatant onto fresh target cells every 3 d. To compare
the ability of CD4-Ig and CD4-VLPs to suppress viral replica-
tion, the viral swarm was distributed into multiple wells and
exposed to their respective IC80s and IC95s for 1 h before fresh
target cells were added. This cycle was repeated every 3 d, and a
total of six cycles were completed. On day 3, HIV-1–induced
GFP expression in Rev-A3R5 cells was measured by flow
cytometry, which demonstrated that both inhibitors suppressed
infection rates effectively (Fig. 6A). After four cycles (day 12),
18722 | www.pnas.org/cgi/doi/10.1073/pnas.2010320117 Hoffmann et al.
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infection rates increased to >4% in the presence of 17.5 μg/mL
CD4-Ig (IC80) for all replicates, which was set as a threshold to
indicate viral escape. CD4-Ig concentrations were doubled to
35 μg/mL for the next cycle to assess whether the viral swarms
were still sensitive to higher inhibitor concentrations. No signs of
viral escape were observed for all other conditions at this point.
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After cycles 5 and 6 (days 15 and 18), infection rates also increased
in the presence of 22.5 μg/mL CD4-Ig (IC95), and viral escape was
observed for two of three replicates (Fig. 6A). Interestingly, in-
fection rates for CD4-Ig (IC80) remained above 4% for two of
three replicates even after the concentration was increased to
70 μg/mL after the fifth cycle. Infection rates remained low for
CD4-VLPs at both concentrations, suggesting that a therapeutic
that presents clusters of CD4 is more effective than traditional
CD4-based inhibitors in controlling HIV-1 replication and pre-
venting viral escape.
A modified version of a recently published in vitro evolution
protocol (36) was used to evaluate whether HIV-1 can escape
when intermittently exposed to increasing CD4-VLP concen-
trations. As above, the diversified HIV-1YU2 swarm was exposed
to CD4-Ig and CD4-VLPs at starting concentrations of 17.5 μg/mL
and 5 × 108 VLPs/mL, respectively, for 1 h, followed by the
addition of fresh target cells. After 3 d, infection rates were
assessed under a fluorescent microscope, and the cycle was re-
peated in the absence of inhibitor to enable HIV-1 replication
and ensure sufficient viral titers for the next selection cycle. This
6-d on/off cycle was repeated 15 times (90 d), and inhibitor
concentrations were gradually increased to final concentrations
of 280 μg/mL of CD4-Ig and 1.6 × 1010 CD4-VLPs/mL. To
evaluate whether the selected viral swarms were resistant to the
inhibitors, in vitro neutralization assays were performed. The
diversified HIV-1YU2 control swarm that was continuously pas-
saged in the absence of any inhibitor remained as sensitive as
YU2wt to CD4-Ig (IC50 = 0.91 μg/mL) and CD4-VLPs (IC50 =
0.02 μg p24/mL) (Fig. 6B); however, the HIV-1YU2 swarm that
was intermittently exposed to increasing CD4-Ig concentrations
was completely resistant to CD4-Ig (IC50 >100 μg/mL). In con-
trast, the viral swarm that was passaged in the presence of CD4-
VLPs remained as sensitive to CD4-VLPs as the control swarm
(IC50 = 0.014 μg p24/mL) (Fig. 6B). Importantly, CD4-VLPs also
potently neutralized the CD4-Ig–resistant swarm (IC50 = 0.009
μg p24/mL), confirming that escape pathways against conven-
tional CD4-based inhibitors are ineffective against CD4-VLPs.
These results demonstrate that decoy therapeutics designed to
present clusters of CD4 have the potential to effectively control
HIV-1 replication and prevent viral escape.
Discussion
Here we show that virus-like nanoparticles that mimic HIV-1
target cells by presenting an array of CD4 molecules neutralize
HIV-1 with enhanced potency and breadth compared with con-
ventional CD4-based inhibitors and bNAbs. In vivo studies in
HIV-1YU2–infected hu-mice showed that intermittent sub-
neutralizing CD4-CCR5-VLP plasma concentrations induced
recurring CD4bs mutations in Env that reduced viral fitness and
neutralization sensitivity to sCD4 and CD4-Ig in vitro, but all
mutant viruses remained as sensitive as wild-type virus to CD4-
VLPs at neutralizing concentrations. In vitro evolution studies
demonstrated that CD4-VLPs effectively controlled HIV-1 rep-
lication, and viral escape was not observed. These results provide
an explanation for the lack of efficacy of conventional CD4-
based inhibitors and motivate the development of therapeutic
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strategies that more accurately mimic HIV-1 target cells to
prevent viral escape and provide sustained suppression of HIV-1.
The enhanced neutralization potency and breadth of CD4-
VLPs implies that membrane-associated display of multiple
CD4 molecules is a more accurate mimic of the HIV-1 target cell
compared with monovalent or bivalent CD4-based inhibitors. Cell
surface CD4 receptors colocalize in nanoclusters that contain ∼4
to 15 molecules of CD4 (37, 38), which would facilitate multiva-
lent binding to HIV-1 Envs. Because Env spikes are trimeric, each
Env can bind up to three CD4 receptors, and multiple Envs may
be engaged during the cell entry process (39, 40), leading to avidity
effects. Compared with soluble CD4-based therapeutics, such as
sCD4 and CD4-Ig, CD4-VLPs required >12,000-fold fewer copies
of CD4 to neutralize a diverse panel of HIV-1 strains. This sug-
gests that multiple CD4–Env interactions between CD4-VLPs and
HIV-1 virions were formed, making it nearly impossible for HIV-1
to dissociate from CD4-VLPs and thereby minimizing the number
of VLPs required to neutralize HIV-1. Cryo-ET imaging of CD4-
VLPs is consistent with the involvement of distinct CD4 nano-
clusters on a single VLP in neutralizing multiple virions simulta-
neously. Moreover, a single HIV-1 virion could be completely
neutralized by two to four CD4-VLPs, as bound VLPs would
sterically hinder the virus from interacting with target cells. The
relatively large sizes of CD4-VLPs likely also prevented the en-
hancement of HIV-1 infection of target cells in vitro, which has
been observed for sCD4 at low concentrations (41).
Twice-daily IP injections of large doses of CD4-CCR5-VLPs
produced only intermittent subneutralizing plasma concentra-
tions in hu-mice, likely due to rapid clearance by hepatic sinu-
soidal endothelial cells, which have been shown to clear
nanoparticles at a rate of up to 108 particles/min (31). As for
conventional CD4-based inhibitors, interactions with class II
major histocompatibility complex (MHC) proteins presented on
antigen-presenting cells could shorten the half-life of CD4-
CCR5-VLPs. Although human antigen-presenting cells have
been shown to be generated in the hu-mouse model used in this
study (42, 43), the bioavailabilities of control VLPs and CD4-
CCR5-VLPs were similarly poor, suggesting that low VLP
concentrations were not related to binding to human class II
MHC-expressing cells. Despite poor bioavailability, intermittent
subneutralizing CD4-CCR5-VLP concentrations elicited recurrent
mutations in the CD4bs in circulating viruses. In vitro neutrali-
zation assays showed that YU2 viruses with these mutations were
as sensitive to CD4-VLPs and CD4-CCR5-VLPs as the wild-type
YU2 virus. We postulate that the mutations provided an ad-
vantage in the presence of short-lived subneutralizing CD4-
CCR5-VLP concentrations, but did not confer resistance to
neutralizing concentrations of CD4-VLPs and CD4-CCR5-
VLPs. It is possible that the mutations protected the virus during
short periods immediately after injections when there were rel-
atively high plasma CD4-CCR5-VLP concentrations and/or
protected the virus against constant exposure to low CD4-CCR5-
VLP concentrations. In contrast, all mutant viruses were 30-fold
less sensitive to sCD4 and CD4-Ig. For three of the four muta-
tions, this loss of neutralization sensitivity was accompanied by
only a fourfold to sevenfold reduction in infectivity. These results
confirm that the ability of Env to bind multiple CD4 receptors on
the target cell with avidity provides an escape route for HIV-1
against sCD4 and CD4-Ig, as the virus is able to tolerate CD4bs
mutations that lower the intrinsic binding affinity for monomeric
sCD4 or bivalent CD4-Ig without considerable fitness cost.
Our in vitro evolution experiments show that CD4-VLPs ef-
fectively suppressed viral replication at neutralizing concentra-
tions, and that intermittent exposure to increasing CD4-VLP
concentrations failed to select resistant viral swarms. This evo-
lution strategy has been shown to generate viral populations
completely resistant to CD4-Ig and the CD4bs bNAb NIH45-46
(36). A modest loss in viral sensitivity was also observed for the
potent antibody-like inhibitor eCD4-Ig, a fusion of CD4-Ig and a
CCR5-mimetic sulfopeptide that protected rhesus macaques
from simian-HIV challenge following delivery using an adeno-
associated virus vector (44). Similar to eCD4-Ig, viral swarms
resistant to CD4-Ig remained sensitive to CD4-VLPs, demon-
strating that escape pathways that are effective against conven-
tional CD4-based inhibitors do not enable HIV-1 to escape
against therapeutics that more accurately mimic HIV-1 target
cells. Overall, our results suggest that effective viral escape
against CD4-VLPs is difficult as the neutralization sensitivity to
the therapeutic and the ability to infect target cells decrease
concomitantly, thus forcing HIV-1 to become progressively less
infectious.
CD4-VLPs were >100-fold more potent against a globally
representative virus panel than the CD4bs bNAb 3BNC117 when
comparing the required numbers of CD4 molecules vs. IgG Fabs.
Importantly, CD4-VLPs were >12,000-fold more potent against
three viral strains that were poorly neutralized by 3BNC117 and
also potently neutralized two clinical viral isolates that were
partially or completely resistant to 3BNC117 and other bNAbs.
Therapeutics that present multiple copies of CD4 tethered to a
surface have two potential advantages over bNAbs that could
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Fig. 6. CD4-VLPs suppress HIV-1 replication and prevent viral escape
in vitro. (A) In vitro evolution experiment comparing the ability of CD4-Ig
and CD4-VLPs to suppress HIV-1 replication. Before the experiment, a di-
versified viral swarm had been generated by passaging replication-
competent HIV-1YU2 on Rev-A3R5 CD4
+ T cells for 21 d. On day 0, the viral
supernatant was distributed into multiple wells, and IC80 (red) and IC95 (blue)
concentrations of CD4-Ig (Top) or CD4-VLPs (Bottom) were added. After 1 h,
fresh Rev-A3R5 cells were added, and infection rates were determined by
measuring HIV-1–induced GFP expression by flow cytometry after 72 h. This
cycle was repeated every 3 d, and a total of six cycles were completed. An
infection rate >4% was set as a threshold to indicate viral escape (dashed
line), and inhibitor concentrations were doubled (*) for replicates that sur-
passed this threshold for the next cycle. (B) In vitro neutralization assays for
CD4-Ig (Top) and CD4-VLPs (Bottom) against HIV-1YU2 swarms that had been
extensively passaged in the presence of no inhibitor (red), CD4-Ig (blue), or
CD4-VLPs (green) (Methods). Inhibitor concentrations are shown as protein
concentrations for CD4-Ig and as p24 concentrations for CD4-VLPs (Fig. 2C
and Methods). Data points are presented as the mean ± SD of duplicate
measurements.
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promote greater neutralization breadth and resistance to viral
escape: (i) anti-Env IgGs (and CD4-Ig) are unlikely to use avidity
effects to bind HIV-1 Env, because the low spike density on the
viral surface and the distribution of epitopes on the Env trimer
result in primarily monovalent binding that is vulnerable to escape
through mutation of HIV-1 Env (16, 17); and (ii) although HIV-1
can mutate to become resistant to any single antibody (5), it must
retain the ability to interact with its receptor to infect cells.
In summary, our results demonstrate that nanoparticles that
mimic HIV-1 target cells by presenting multiple copies of
membrane-associated CD4 neutralize HIV-1 with enhanced po-
tency, breadth, and resistance to viral escape compared with
conventional CD4-based inhibitors and CD4bs bNAbs. Therefore,
we postulate that therapeutics that mimic viral target cells could
prevent escape and permanently control HIV-1 infection by ex-
posing a universal vulnerability—the requirement to bind clusters
of CD4 on a target cell—that is potentially inherent to all HIV-1
strains and variants. Since direct injections of CD4-VLPs failed to
achieve therapeutic concentrations in vivo, alternative therapeutic
and/or delivery strategies that ensure durable bioavailability and
minimize the requirement for repeated administrations need to be
developed to translate this concept into a clinically feasible func-
tional cure therapy.
Materials and Methods
VLP Production. VLPs were produced by transiently transfecting Expi293 cells
(Life Technologies) grown in Expi293 expression media (Life Technologies) on
an orbital shaker at 37 °C and 8% CO2. Cells were transfected with a plasmid
vector expressing Rev-independent HIV-1 Gag-Pol (pHDM-Hgpm2 plasmid;
PlasmID Repository, Harvard Medical School) or a Gag-EGFP fusion protein
(HIV-1 HXB2 Gag-EGFP expression vector; NIH AIDS Reagent Program). To
generate CD4-VLPs and CD4-CCR5-VLPs, cells were cotransfected with a
second plasmid (cDNA sequences of CD4 and CCR5 subcloned into the
pHAGE-CMV-IRES-ZsGreen plasmid; PlasmID Repository, Harvard Medical
School) encoding CD4 alone or CD4 and CCR5 at a DNA ratio of 4:1 Gag-
Pol:CD4-(CCR5). Control VLPs were generated by expression of HIV-1 Gag-Pol
alone. Expi293 cells were also transfected with CD4 in the absence of Gag-
Pol to make CD4+ extracellular vesicles. At 48 to 72 h posttransfection, cells
were centrifuged at 350 × g for 8 min, and supernatants were collected and
passed through a 0.45-μm syringe filter.
VLP Purification. For in vitro neutralization experiments, VLPs were concen-
trated and buffer-exchanged into TZM-bl cell culture medium in Amicon
Ultra-15 centrifugal filter units with a 100-kDa molecular weight cutoff
(Millipore). For initial experiments, VLPs were isolated by ultracentrifugation
at 28,000 rpm (96,000 × g) for 2 h at 4 °C using a SW32 Ti rotor and a
Beckman L8-80M ultracentrifuge (Beckman Coulter) on a 20% wt/vol sucrose
cushion. The supernatant was carefully aspirated, and the pellet was resus-
pended in 500 μL of culture medium at 4 °C overnight.
For quantitative Western blot analysis and cryo-ET imaging studies, 50 mL
of filtered supernatant (combined from five independent CD4-VLP produc-
tions) was concentrated and buffer-exchanged into 500 μL of PBS by sucrose
cushion ultracentrifugation as described above, centrifuged at 10,000 × g for
15 min, passed through a 0.45-μm syringe filter, and further purified by size
exclusion chromatography on a Superose 6 10/300 column (GE Healthcare)
equilibrated with 20 mM NaHPO4 (pH 7.4) and 150 mM NaCl. Fractions were
collected and loaded onto 4 to 20% polyacrylamide gels (Bio-Rad) and
stained with InstantBlue protein stain (Expedeon).
For in vivo experiments, control and CD4-CCR5-VLPs were concentrated
from 1,000 mL to 5 mL in Slide-A-Lyzer dialysis cassettes (Thermo Fisher
Scientific) that were immersed in a 40% wt/vol PEG (20 kDa) in ultrapure
water concentrating solution (Thermo Fisher Scientific) and then buffer-
exchanged into PBS.
VLP Quantification. VLP concentrations were quantified using a lentivirus-
associated p24 ELISA kit (Cell Biolabs). To ensure accurate quantification of
VLPs for in vitro neutralization studies, we used Gag-Pol instead of Gag-EGFP
for generating VLPs, because detection of the Gag-encoded capsid protein
p24 is less efficient for immature Gag than for mature Gag that had been
processed by the HIV-1 protease encoded within Pol after budding (45). VLP
concentrations were calculated using the following equation in accordance
with the manufacturer’s directions: 1 ng p24 = 1.25 × 107 VLPs (46, 47),
which assumes that each VLP contains 2,000 molecules of p24 (20, 21).
In Vitro Neutralization Assays. The ability of VLPs to neutralize HIV-1 was
evaluated using a pseudovirus-based TZM-bl assay (22). Pseudoviruses with
Envs from YU2wt, YU variants, and strains from a 12-strain global HIV-1 panel
(26) were generated in HEK293T cells as described previously (48). Serial
dilutions of control VLPs, CD4-VLPs, and CD4-CCR5-VLPs were incubated with
pseudovirus for 1 h at 37 °C. TZM-bl cells (NIH AIDS Reagents Program) that
express a Tat-inducible luciferase reporter gene were added, and lumines-
cence was measured after 48 h. The HIV-1 neutralization activity of CD4-VLPs
was compared with that of sCD4, CD4-Ig, and the CD4bs bNAb 3BNC117.
Neutralization assays were also performed against primary virus isolates
obtained from the latent reservoirs of two HIV-1–infected patients who
received repeated infusions of 3BNC117 (27). Viruses were isolated from
peripheral blood mononuclear cells by a quantitative and qualitative viral
outgrowth assay (Q2VOA) as described previously (49).
The number of CD4 molecules/mL required to achieve 50% neutralization
was calculated by multiplying the VLP concentration (derived from the p24
ELISA) at the IC50 (derived from an in vitro neutralization assay) by the av-
erage number of CD4 copies per VLP (derived from quantitative Western
blot analysis). For sCD4 D1D2 (26 kDa), CD4-Ig (100 kDa), and 3BNC117 (150
kDa), the numbers of CD4 molecules/mL (sCD4, CD4-Ig) or Fab molecules/mL
(3BNC117) were calculated by converting the measured IC50 values (in μg/mL)
to molar concentrations. The respective numbers of inhibitor molecules were
then derived from molar IC50 concentrations using Avogadro’s number. The
numbers of inhibitor molecules (CD4 or Fab) were then multiplied by a
factor of one (sCD4) or two (CD4-Ig, 3BNC117), depending on whether the
inhibitor molecule contained one or two CD4/Fab copies. IC50 values calcu-
lated from independent assays generally agreed to within twofold to
fourfold (SI Appendix, Fig. S3).
In Vivo Studies. Studies in hu-mice were performed in accordance with the
recommendations in the NIH’s Guide for the Care and Use of Laboratory
Animals. The protocol was reviewed and approved by The Rockefeller Uni-
versity’s Institutional Animal Care and Use Committee, and experiments
were designed in accordance with established guidelines at The Rockefeller
University (protocol no. 13618-H).
Hu-mice were generated as described previously (50). In brief, human
CD34+ hematopoietic stem cells were obtained from human fetal livers
(Human Fetal Tissue Repository) and injected intrahepatically into irradiated
nonobese diabetic Rag1−/− IL2rgnull (NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ)
mice (The Jackson Laboratory). Half-life studies for VLPs were performed in
uninfected hu-mice. CD4-CCR5-VLPs (610 ng of p24) were injected IP into
five hu-mice, and a single blood sample was taken from each animal after
20 min, 1 h, 2 h, 4 h, or 6 h. Plasma CD4-CCR5-VLP concentrations were
measured by lentivirus-associated p24 ELISA (Cell Biolabs).
For treatment experiments, hu-mice were infected with HIV-1YU2, and
viral plasma loads were measured by qRT-PCR at 10 d postinfection as de-
scribed previously (50). Infected hu-mice were distributed into four treat-
ment groups: no treatment (group I), twice-daily IP injections of 480 ng p24
of control VLPs (group II) or CD4-CCR5-VLPs (group III), or twice-weekly ad-
ministration of 1 mg of the bNAb 10–1074 (group IV). Treatments were
continued for a total of 10 d, and viral plasma loads were measured on days
3, 6, and 10 by qRT-PCR as described previously (50).
Viral Fitness Assay. To evaluate the ability of HIV-1YU2 Env mutants to enter
and infect target cells, a previously described infection assay (51, 52) was
used with minor modifications. Here 40 pg p24 of YU2wt or mutant YU2
pseudoviruses (quantified by lentivirus-associated p24 ELISA; Cell Biolabs)
were added to TZM-bl reporter cells in the presence of 30 μg/mL DEAE-
dextran. After a 48-h incubation at 37 °C, cells were lysed, and lumines-
cence was measured after the addition of britelite plus (PerkinElmer). The
average luminescence among eight 8 replicates was calculated for YU2wt
and each YU2 variant, and the experiment was repeated three times with
different pseudovirus batches. The viral entry fitness of the YU2 mutant
viruses was calculated as a function of the reduction in average lumines-
cence compared with YU2wt.
In Vitro Evolution Assays. Replication-competent HIV-1NL4-3 carrying the HIV-
1YU2 envelope (53) was passaged on Rev-A3R5 CD4
+ T cells (35) (Cube Bio-
Systems) for 21 d to diversify the viral population. Rev-A3R5 cells were
maintained in RPMI 1640 medium supplemented with 10% FBS, 1% pen-
strep, 1% L-glutamine, 1 mg/mL geneticin, and 1 μg/mL puromycin at 37 °C
and 5% CO2. To test whether CD4-VLPs can suppress viral replication, 30 μL
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of viral supernatant was added to multiple wells on a 48-well plate. Previ-
ously determined IC80s and IC95s of CD4-Ig (17.5 and 22.5 μg/mL) and CD4-
VLPs (5 × 108 and 1.25 × 109 VLPs/mL) or no inhibitor were added to the wells
in triplicate in the presence of 5 μg/mL DEAE-dextran, and then media was
added for a final volume of 500 μL. After 1 h of incubation at 37 °C, 5 × 104
Rev-A3R5 cells were added, and the plates were incubated for 16 h at 37 °C.
The next day, cells were centrifuged at 350 × g for 8 min, supernatants were
removed, and cells were resuspended in 500 μL of fresh medium. After 48 h,
infection rates were quantified by measuring HIV-1–induced GFP expression
in Rev-A3R5 cells by flow cytometry (MACSQuant; Miltenyi Biotec). For the
second cycle, 350 μL of viral supernatants for each condition were trans-
ferred into fresh 48-well plates and inhibitors, DEAD-dextran, and cells were
added as in cycle 1. A total of six cycles were performed, and infection rates
were determined after cycles 4 to 6. Infection rates in the absence of in-
hibitor were maintained at ∼10% infected cells, and to account for varia-
tions between cycles, infection rates were normalized to a viral control
infection of 10%. Viral escape was defined as >4% infected cells (60%
neutralization), and inhibitor concentrations were increased twofold for
replicates that surpassed this threshold for the next cycle.
A modified version of a previously described in vitro evolution protocol
(36) was used to evaluate whether HIV-1 can escape from CD4-VLPs when
intermittently exposed to increasing inhibitor concentrations. Here 10 to
20 μL of viral supernatant was added to multiple wells on a 96-well plate,
then CD4-Ig and CD4-VLPs were added at starting concentrations of 17.5 μg/
mL and 5 × 108 VLPs/mL, respectively, in the presence of 5 μg/mL DEAE-
dextran, and finally medium was added for a final volume of 200 μL. After
a 1-h incubation at 37 °C, 2.5 × 104 cells were added, and the plates were
incubated at 37 °C. After 8 h, cells were centrifuged, supernatants were
removed, and cells were resuspended in 200 μL of fresh medium. After 64 h,
infection rates were assessed using a fluorescent microscope (Zeiss AX10).
The second cycle was performed in the absence of inhibitor to enable HIV-1
replication and ensure sufficient viral titers for the next selection cycle. This
6-d on/off cycle was repeated 15 times (90 d), and inhibitor concentrations
were doubled every two to four cycles to final concentrations of 280 μg/mL
of CD4-Ig and 1.6 × 1010 CD4-VLPs/mL. To maintain infections at higher in-
hibitor concentrations, up to 150 μL of viral supernatant was passaged, and
repeated cycles in the absence of inhibitor were performed. After the final
cycle, viral supernatants for each condition (no inhibitor, CD4-Ig, and CD4-
VLPs) were collected and TZMbl assays were performed as described above.
Statistical Analysis. Concentrations at which half-maximal neutralization was
observed (IC50 values) were calculated using software in the HIV Antibody
Database (54). The levels of conservation of the mutated residues and the
respective substitutions observed in env sequences obtained from HIV-
1–infected and CD4-CCR5-VLP–treated hu-mice were determined through
filtered web alignment of HIV-1 sequences in the Los Alamos National
Laboratory HIV Database (https://www.hiv.lanl.gov/).
Data and Materials Availability. All data associated with this study are
available in the main text or SI Appendix.
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